Every one of those 1 sits in a single category, market-trends. NIPER Raebareli is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 2 original sources on average, compared with 3 for the broader beat in this window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Roche Pharma
Every one of those 1 sits in a single category, market-trends. NIPER Raebareli is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 2 original sources on average, compared with 3 for the broader beat in this window. At 5, the average consequence score sits below the same-window beat average of 5.9. Roche Pharma appears in 1 tracked Healthcare story from March 19, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 30 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Roche Pharma. Shared-story counts are live from our verified record — not editorial picks.
Roche Pharma and NIPER Raebareli have signed a Memorandum of Understanding to enhance pharmaceutical education and research capability building in India. This collaboration focuses on bridging the gap between academic research and industry requirements to foster innovation in the domestic healthcare sector.